Archives: Speakers

Lisbet Groes, Ph.D., e*MMBS, is Associate Director, Clinical Operations at Ascendis Pharma. With over 25 years in clinical development, she brings deep expertise in global trial execution, including leading Phase III programs in Japan. Lisbet has hands-on experience with CRO selection, PMDA interactions, trial execution, and inspection readiness. She is known for her strategic mindset, cross-cultural collaboration, and ability to foster high-performing sponsor-CRO partnerships.

Karin has a MSc in Pharmacy and Pharmaceutical Biosciences from Uppsala University in Sweden.  She is passionate about drug development that aims to meet unmet medical needs. Karin has 19 years of experience in life science industry and has worked for Astra Zenica, McNeil AB, a Johnson&Johnson company, and currently works at Alligator Bioscience AB since 4 years as Dir ClinOps. Alligator is a company specialized in immune oncology drug development.

Expert in tobacco identity and age verification requirements.

Asiyah Nawab, MSc, is an Analyst at GlobalData’s London office with the Immunology team. She is involved in the production of in-depth forecasting reports, opportunity assessments, and competitive landscape analysis reports for immunology-related areas. Additionally, Asiyah has extensive research experience in the field of Pharmaceutics, with her research in the encapsulation of drugs within microparticles using emulsion electrospraying, supplemented through in vitro bacterial studies. Asiyah holds a Master of Science in Pharmaceutics from University College London (UCL), and a Bachelor’s degree in Biochemistry from King’s College London.

Chris has over 25 years of experience in the pharmaceutical industry. Over the past 10 years, he has focused on Market Access, Pricing, and Health Economics and Outcomes Research (HEOR), particularly in oncology. He is the Head of Market Access, Pricing, and HEOR for ex-US countries at Immunocore, a small biotech company based in Oxford (UK) and Rockville (USA). Chris is responsible for negotiating reimbursement and access across more than 30 countries.

Immunocore, which originated from Oxford University over 25 years ago, recently launched its first oncology medicine, tebentafusp, for the treatment of a rare cancer with no standard of care and a short life expectancy. The exceptional achievements of Immunocore and tebentafusp were recognised with the prestigious Prix Galien awards in both France and Germany. The launch is regarded as one of the most successful first launches for a biotech company.

Prior to joining Immunocore, Chris supported oncology efforts at AstraZeneca. Before moving into Market Access, he worked in research at GSK and SmithKline Beecham, and in pathology within the UK NHS. Chris holds a master’s degree in Economic Evaluation in Healthcare and a PhD in Biochemistry.

Beth Chamblin has 25 years of experience in Pharmaceutical/BioPharmaceutical development, including over 15 years in global clinical project management and 4 years in oncology project management. At IQVIA Biotech, she specializes in strategic oversight of late-phase global clinical programs, supporting emerging biotech companies. Beth has managed global Phase I-III studies across multiple regions and has expertise in novel trial designs. She also leads a team of 10 project managers/directors, providing mentoring and support. Her broad experience allows her to align each study with a company’s long-term goals, ensuring project success.

Eugenia Perozo is the editor for Investment Monitor, where she reports on political and economic trends affecting global FDI flows. She has covered the onslaught of US tariffs, travelling to an investment conference in Washington DC to report on how these have affected foreign business sentiment. She holds a Philosophy, Politics and Economics degree from Warwick University.